- In September 2024, Evotec shares jumped 6% after announcing a technology development partnership with Novo Nordisk centered on cell therapy. The collaboration involves funding for development activities in Germany and Italy, along with upfront payments, potential milestone achievements, and royalty incentives. Dr. Cord Dohrmann, Evotec's Chief Scientific Officer, expressed optimism about creating innovative stem cell-based therapies through this partnership
- In September 2024, Tremfya (guselkumab) was FDA-approved for adults with moderately to severely active ulcerative colitis, in addition to its approvals for plaque psoriasis and psoriatic arthritis. It is the first dual-acting interleukin-23 inhibitor for this condition, showing significant remission rates in the QUASAR study. Administered as a 200 mg intravenous induction dose, it follows with subcutaneous maintenance doses of 100 mg every 8 weeks or 200 mg every 4 weeks. This approval highlights Johnson & Johnson's commitment to advancing treatments for inflammatory bowel disease
- In July 2024, Biogen has acquired Human Immunology Biosciences (HI-Bio), enhancing its immunology pipeline with felzartamab, a promising therapeutic candidate. The acquisition will advance felzartamab into Phase 3 trials for various indications. Positive interim results have been reported in Phase 2 studies for IgA nephropathy and antibody-mediated rejection
- In July 2024, Biogen has acquired Human Immunology Biosciences (HI-Bio), enhancing its immunology pipeline with felzartamab, a promising therapeutic candidate. The acquisition will advance felzartamab into Phase 3 trials for various indications. Positive interim results have been reported in Phase 2 studies for IgA nephropathy and antibody-mediated rejection
- In July 2024, AstraZeneca had successfully acquired Amolyt Pharma for up to USD 1.05 billion, enhancing its Alexion Rare Disease pipeline. This includes the Phase III peptide eneboparatide for hypoparathyroidism, expanding AstraZeneca's focus on rare endocrine diseases and calcium regulation treatments
- In June 2024, Aptar Digital Health partnered with SHL Medical to enhance connected device technologies by integrating its SaMD platform. This collaboration aimed to improve the patient experience during self-administration of injectable therapies, supporting better adherence and disease management for patients
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA SELF-INJECTIONS MARKET
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 THERAPEUTICS LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET APPLICATION COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 CUSTOMIZATIONS
5 NORTH AMERICA SELF-INJECTIONS MARKET: REGULATIONS
5.1 REGULATORY AUTHORITIES IN THE ASIA-PACIFIC REGION
5.1.1 AUSTRALIA
5.1.2 CHINA
5.1.3 INDIA
5.2 REGULATORY SUBMISSIONS
5.2.1 PRE-SUBMISSION ACTIVITIES
5.2.2 DEVELOPMENT OF TECHNICAL DOCUMENTATION
5.3 CLINICAL EVALUATION
5.4 REGULATORY SUBMISSION PREPARATION
5.5 SUBMISSION TO REGULATORY AUTHORITY
5.6 REVIEW AND EVALUATION BY REGULATORY AUTHORITY
5.7 APPROVAL AND MARKET AUTHORIZATION
5.8 POST-MARKET SURVEILLANCE
5.9 RENEWAL AND COMPLIANCE
5.1 ASEAN MEDICAL DEVICE DIRECTIVE (AMDD)
5.11 ADOPTION OF NORTH AMERICA STANDARDS (ISO AND IEC)
5.12 COLLABORATION VIA APEC REGULATORY HARMONIZATION STEERING COMMITTEE
5.13 CLINICAL DATA HARMONIZATION
5.14 COMMON TECHNICAL DOCUMENT (CTD) FORMAT
5.15 POST-MARKET SURVEILLANCE AND REPORTING HARMONIZATION
5.16 MUTUAL RECOGNITION AGREEMENTS (MRAS)
5.17 TRAINING AND CAPACITY BUILDING INITIATIVES
5.18 NORTH AMERICA REGULATORY SCENARIO
5.19 MEDICAL DEVICE CLASSIFICATION
5.2 REGULATORY SUBMISSIONS
5.21 EUROPE REGULATORY SCENARIO
5.22 REGULATORY SUBMISSIONS
5.23 MIDDLE EAST AND AFRICA REGULATORY SCENARIO
5.24 SOUTH AMERICA REGULATORY SCENARIO
5.25 INTERNATIONAL HARMONIZATION
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF CHRONIC DISEASE
6.1.2 TECHNOLOGICAL ADVANCEMENT IN SELF INJECTIONS
6.1.3 INCREASE IN PATIENT AUTONOMY
6.1.4 RISE IN MOBILE HEALTH APPLICATIONS
6.2 RESTRAINTS
6.2.1 HIGH COST OF SELF INJECTORS
6.2.2 REGULATORY HURDLES AND NEED FOR PROPER TRAINING FOR SELF-INJECTION DEVICES
6.3 OPPORTUNITIES
6.3.1 GOVERNMENT INITIATIVES TO SELF-INJECTIONS
6.3.2 INCREASED RESEARCH AND DEVELOPMENT FOR SELF-INJECTION
6.3.3 GROWING DEMAND FOR BIOLOGICS AND PERSONALIZED MEDICINE
6.4 CHALLENGES
6.4.1 PATIENT RELUCTANCE TOWARDS NEEDLES
6.4.2 ENVIRONMENTAL CONCERNS WITH SELF-INJECTIONS
7 NORTH AMERICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 SELF-INJECTION DEVICES
7.3 SELF-INJECTION FORMULATION
8 NORTH AMERICA SELF-INJECTIONS MARKET, BY DOSAGE FORM
8.1 OVERVIEW
8.2 SINGLE DOSE
8.3 MULTI-DOSE
9 NORTH AMERICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION
9.1 OVERVIEW
9.2 SUBCUTANEOUS
9.3 INTRA MUSCULAR
9.4 OTHERS
10 NORTH AMERICA SELF-INJECTIONS MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 AUTOIMMUNE DISEASES
10.3 PAIN MANAGEMENT
10.4 EMERGENCY DRUGS
10.5 ONCOLOGY
10.6 HORMONAL DISORDERS
10.7 OTHERS
11 NORTH AMERICA SELF-INJECTIONS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 ADULT
11.3 GERIATRIC
11.4 PEDIATRIC
12 NORTH AMERICA SELF-INJECTIONS MARKET, BY GENDER
12.1 OVERVIEW
12.2 MALE
12.3 FEMALE
13 NORTH AMERICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL
13.1 OVERVIEW
13.2 DIRECT TENDER
13.3 HOSPITAL PHARMACY
13.4 ONLINE PHARMACY
13.5 OTHERS
14 NORTH AMERICA SELF-INJECTIONS MARKET, BY REGION
14.1 NORTH AMERICA
15 NORTH AMERICA SELF-INJECTIONS MARKET: COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILES
17.1 NOVO NORDISK
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 JOHNSON & JOHNSON SERVICES, INC.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 BIOGEN
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 PRODUCT PORTFOLIO
17.3.4 RECENT DEVELOPMENT
17.4 AMGEN INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 SANOFI
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 ABBVIE INC.
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 COMPANY SHARE ANALYSIS
17.6.4 PRODUCT PORTFOLIO
17.6.5 RECENT DEVELOPMENT
17.7 YPSOMED
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BD
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 ASTRAZENECA
17.9.1 COMPANY SNAPSHOT
17.9.2 REVENUE ANALYSIS
17.9.3 PRODUCT PORTFOLIO
17.9.4 RECENT DEVELOPMENTS
17.1 APTARGROUP, INC.
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENTS
17.11 BAYER
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 BAUSCH HEALTH COMPANIES INC.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.13 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENTS
17.14 CREDENCE MEDSYSTEMS, INC.
17.14.1 COMPANY SNAPSHOT
17.14.2 PRODUCT PORTFOLIO
17.14.3 RECENT DEVELOPMENT
17.15 DALI MEDICAL DEVICES
17.15.1 COMPANY SN.APSHOT
17.15.2 PRODUCT PORTFOLIO
17.15.3 RECENT DEVELOPMENT
17.16 ENABLE INJECTIONS
17.16.1 COMPANY SNAPSHOT
17.16.2 PRODUCT PORTFOLIO
17.16.3 RECENT DEVELOPMENTS
17.17 E3D ELCAM DRUG DELIVERY DEVICES
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 F. HOFFMANN-LA ROCHE LTD
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 GSK PLC
17.19.1 COMPANY SNAPSHOT
17.19.2 REVENUE ANALYSIS
17.19.3 PRODUCT PORTFOLIO
17.19.4 RECENT DEVELOPMENTS
17.2 GERRESHEIMER AG
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENTS
17.21 HASELMEIER
17.21.1 COMPANY SNAPSHOT
17.21.2 PRODUCT PORTFOLIO
17.21.3 RECENT DEVELOPMENT
17.22 IPSEN BIOPHARMACEUTICALS, INC.
17.22.1 COMPANY SNAPSHOT
17.22.2 REVENUE ANALYSIS
17.22.3 PRODUCT PORTFOLIO
17.22.4 RECENT DEVELOPMENT
17.23 LILLY
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 MIDAS PHARMA GMBH
17.24.1 COMPANY SNAPSHOT
17.24.2 PRODUCT PORTFOLIO
17.24.3 RECENT DEVELOPMENT
17.25 MERCK & CO., INC.,
17.25.1 COMPANY SNAPSHOT
17.25.2 REVENUE ANALYSIS
17.25.3 PRODUCT PORTFOLIO
17.25.4 RECENT DEVELOPMENT
17.26 NOVARTIS AG
17.26.1 COMPANY SNAPSHOT
17.26.2 REVENUE ANALYSIS
17.26.3 PRODUCT PORTFOLIO
17.26.4 RECENT DEVELOPMENTS
17.27 NEMERA
17.27.1 COMPANY SNAPSHOT
17.27.2 PRODUCT PORTFOLIO
17.27.3 RECENT DEVELOPMENT
17.28 OVAL MEDICAL TECHNOLOGIES LTD. (SMC LIMITED)
17.28.1 COMPANY SNAPSHOT
17.28.2 PRODUCT PORTFOLIO
17.28.3 RECENT DEVELOPMENT
17.29 OWEN MUMFORD
17.29.1 COMPANY SNAPSHOT
17.29.2 PRODUCT PORTFOLIO
17.29.3 RECENT DEVELOPMENT
17.3 PFIZER INC.
17.30.1 COMPANY SNAPSHOT
17.30.2 REVENUE ANALYSIS
17.30.3 PRODUCT PORTFOLIO
17.30.4 RECENT DEVELOPMENT
17.30.5 RECENT DEVELOPMENT
17.31 PHILIP MEDSIZE
17.31.1 COMPANY SNAPSHOT
17.31.2 PRODUCT PORTFOLIO
17.31.3 RECENT DEVELOPMENTS
17.32 PHARMAJET.
17.32.1 COMPANY SNAPSHOT
17.32.2 PRODUCT PORTFOLIO
17.32.3 RECENT DEVELOPMENT
17.33 PENJET
17.33.1 COMPANY SNAPSHOT
17.33.2 1.1.4 PRODUCT PORTFOLIO
17.33.3 RECENT DEVELOPMENT
17.34 RECIPHARM AB
17.34.1 COMPANY SNAPSHOT
17.34.2 PRODUCT PORTFOLIO
17.34.3 RECENT DEVELOPMENTS
17.35 SCHOTT PHARMA
17.35.1 COMPANY SNAPSHOT
17.35.2 PRODUCT PORTFOLIO
17.35.3 RECENT DEVELOPMENTS
17.36 SHL MEDICAL AG
17.36.1 COMPANY SNAPSHOT
17.36.2 PRODUCT PORTFOLIO
17.36.3 RECENT DEVELOPMENT
17.37 SOCIÉTÉ INDUSTRIELLE DE SONCEBOZ SA
17.37.1 COMPANY SNAPSHOT
17.37.2 PRODUCT PORTFOLIO
17.37.3 RECENT DEVELOPMENT
17.38 TERUMO CORPORATION
17.38.1 COMPANY SNAPSHOT
17.38.2 REVENUE ANALYSIS
17.38.3 PRODUCT PORTFOLIO
17.38.4 RECENT DEVELOPMENT
17.39 TAKEDA PHARMACEUTICAL COMPANY LIMITED
17.39.1 COMPANY SNAPSHOT
17.39.2 REVENUE ANALYSIS
17.39.3 PRODUCT PORTFOLIO
17.39.4 RECENT DEVELOPMENT
17.4 TEVA PHARMACEUTICALS
17.40.1 COMPANY SNAPSHOT
17.40.2 REVENUE
17.40.3 PRODUCT PORTFOLIO
17.40.4 RECENT DEVELOPMENT
17.41 UCB PHARMA
17.41.1 COMPANY SNAPSHOT
17.41.2 REVENUE
17.41.3 PRODUCT PORTFOLIO
17.41.4 RECENT DEVELOPMENT
17.42 WEST PHARMACEUTICAL SERVICES
17.42.1 COMPANY SNAPSHOT
17.42.2 REVENUE ANALYSIS
17.42.3 PRODUCT PORTFOLIO
17.42.4 RECENT DEVELOPMENTS
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 2 NORTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 3 NORTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 4 NORTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 5 NORTH AMERICA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 6 NORTH AMERICA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 7 NORTH AMERICA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 8 NORTH AMERICA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 9 NORTH AMERICA SELF-INJECTION FORMULATION IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 10 NORTH AMERICA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 11 NORTH AMERICA SINGLE DOSE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 NORTH AMERICA MULTI-DOSE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 13 NORTH AMERICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 14 NORTH AMERICA SUBCUTANEOUS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 NORTH AMERICA INTRA MUSCULAR IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 NORTH AMERICA OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 17 NORTH AMERICA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 18 NORTH AMERICA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 19 NORTH AMERICA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 20 NORTH AMERICA PAIN MANAGEMENT IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 NORTH AMERICA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 NORTH AMERICA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 23 NORTH AMERICA ONCOLOGY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 NORTH AMERICA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 NORTH AMERICA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 NORTH AMERICA OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 27 NORTH AMERICA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 28 NORTH AMERICA ADULT IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 NORTH AMERICA GERIATRIC IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 30 NORTH AMERICA PEDIATRIC IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 32 NORTH AMERICA MALE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA FEMALE IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 NORTH AMERICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA DIRECT TENDER IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 NORTH AMERICA HOSPITAL PHARMACY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA ONLINE PHARMACY IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 NORTH AMERICA OTHERS IN SELF-INJECTIONS MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA SELF-INJECTIONS MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 40 NORTH AMERICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 41 NORTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 42 NORTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 43 NORTH AMERICA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 44 NORTH AMERICA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 45 NORTH AMERICA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 46 NORTH AMERICA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 47 NORTH AMERICA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 NORTH AMERICA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 49 NORTH AMERICA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 50 NORTH AMERICA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 51 NORTH AMERICA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 NORTH AMERICA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 53 NORTH AMERICA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 54 NORTH AMERICA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 55 NORTH AMERICA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 56 NORTH AMERICA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 57 U.S. SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 58 U.S. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 59 U.S. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 60 U.S. SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 61 U.S. AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 62 U.S. PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 63 U.S. WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 64 U.S. NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 65 U.S. SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 66 U.S. SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 67 U.S. SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 68 U.S. AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 U.S. EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 70 U.S. HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 71 U.S. SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 72 U.S. SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 73 U.S. SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 74 CANADA SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 75 CANADA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 CANADA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 77 CANADA SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 78 CANADA AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 79 CANADA PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 80 CANADA WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 81 CANADA NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 CANADA SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 83 CANADA SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 84 CANADA SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 85 CANADA AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 CANADA EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 87 CANADA HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 88 CANADA SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 89 CANADA SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 90 CANADA SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 91 MEXICO SELF-INJECTIONS MARKET, BY PRODUCT TYPE, 2022-2031 (USD MILLION)
TABLE 92 MEXICO SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 93 MEXICO SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 94 MEXICO SELF-INJECTION DEVICES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031(ASP)
TABLE 95 MEXICO AUTO INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 96 MEXICO PEN INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 97 MEXICO WEARABLE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 98 MEXICO NEEDLE-FREE INJECTORS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 MEXICO SELF-INJECTIONS MARKET, BY DOSAGE FORM, 2022-2031 (USD MILLION)
TABLE 100 MEXICO SELF-INJECTIONS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 101 MEXICO SELF-INJECTIONS MARKET, BY APPLICATION, 2022-2031 (USD MILLION)
TABLE 102 MEXICO AUTOIMMUNE DISEASES IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 MEXICO EMERGENCY DRUGS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 104 MEXICO HORMONAL DISORDERS IN SELF-INJECTIONS MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 105 MEXICO SELF-INJECTIONS MARKET, BY AGE GROUP, 2022-2031 (USD MILLION)
TABLE 106 MEXICO SELF-INJECTIONS MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 107 MEXICO SELF-INJECTIONS MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA SELF-INJECTIONS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA SELF-INJECTIONS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA SELF-INJECTIONS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA SELF-INJECTIONS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA SELF-INJECTIONS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA SELF-INJECTIONS MARKET: MULTIVARIATE MODELLING
FIGURE 7 NORTH AMERICA SELF-INJECTIONS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 NORTH AMERICA SELF-INJECTIONS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA SELF-INJECTIONS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA SELF-INJECTIONS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 11 NORTH AMERICA SELF-INJECTIONS MARKET: SEGMENTATION
FIGURE 12 TWO SEGMENTS COMPRISE THE NORTH AMERICA SELF-INJECTIONS MARKET, BY PRODUCT TYPE
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 EXECUTIVE SUMMARY
FIGURE 15 SELF-INJECTION DEVICES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA SELF-INJECTIONS MARKET IN 2024 & 2031
FIGURE 16 DROC ANALYSIS
FIGURE 17 NORTH AMERICA SELF-INJECTIONS MARKET: BY PRODUCT TYPE, 2023
FIGURE 18 NORTH AMERICA SELF-INJECTIONS MARKET: BY PRODUCT TYPE, 2024-2031 (USD MILLION)
FIGURE 19 NORTH AMERICA SELF-INJECTIONS MARKET: BY PRODUCT TYPE, CAGR (2024-2031)
FIGURE 20 NORTH AMERICA SELF-INJECTIONS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 21 NORTH AMERICA SELF-INJECTIONS MARKET: BY DOSAGE FORM, 2023
FIGURE 22 NORTH AMERICA SELF-INJECTIONS MARKET: BY DOSAGE FORM, 2024-2031 (USD MILLION)
FIGURE 23 NORTH AMERICA SELF-INJECTIONS MARKET: BY DOSAGE FORM, CAGR (2024-2031)
FIGURE 24 NORTH AMERICA SELF-INJECTIONS MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 25 NORTH AMERICA SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 26 NORTH AMERICA SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
FIGURE 27 NORTH AMERICA SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 28 NORTH AMERICA SELF-INJECTIONS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 29 NORTH AMERICA SELF-INJECTIONS MARKET: BY APPLICATION, 2023
FIGURE 30 NORTH AMERICA SELF-INJECTIONS MARKET: BY APPLICATION, 2024-2031 (USD MILLION)
FIGURE 31 NORTH AMERICA SELF-INJECTIONS MARKET: BY APPLICATION, CAGR (2024-2031)
FIGURE 32 NORTH AMERICA SELF-INJECTIONS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 33 NORTH AMERICA SELF-INJECTIONS MARKET: BY AGE GROUP, 2023
FIGURE 34 NORTH AMERICA SELF-INJECTIONS MARKET: BY AGE GROUP, 2024-2031 (USD MILLION)
FIGURE 35 NORTH AMERICA SELF-INJECTIONS MARKET: BY AGE GROUP, CAGR (2024-2031)
FIGURE 36 NORTH AMERICA SELF-INJECTIONS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 37 NORTH AMERICA SELF-INJECTIONS MARKET: BY GENDER, 2023
FIGURE 38 NORTH AMERICA SELF-INJECTIONS MARKET: BY GENDER, 2024-2031 (USD MILLION)
FIGURE 39 NORTH AMERICA SELF-INJECTIONS MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 40 NORTH AMERICA SELF-INJECTIONS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 41 NORTH AMERICA SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 42 NORTH AMERICA SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 43 NORTH AMERICA SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 44 NORTH AMERICA SELF-INJECTIONS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 45 NORTH AMERICA SELF-INJECTIONS MARKET: SNAPSHOT (2023)
FIGURE 46 NORTH AMERICA SELF-INJECTIONS MARKET: COMPANY SHARE 2023 (%)
